MDAI
外觀
臨床資料 | |
---|---|
其他名稱 | 5,6-Methylenedioxy-2-aminoindane; 5,6-Methylenedioxy-2-aminoindan; Methylenedioxyaminoindane; Methylenedioxyaminoindan |
給藥途徑 | 口服給藥 |
藥物類別 | Serotonin–norepinephrine releasing agent; Entactogen |
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
作用時間 | 2–6 小時 |
識別資訊 | |
| |
CAS號 | 132741-81-2 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C10H11NO2 |
摩爾質量 | 177.20 g·mol−1 |
3D模型(JSmol) | |
| |
|
MDAI(5,6-亞甲二氧基-2-氨基茚滿,英語:5,6-methylenedioxy-2-aminoindane)是一種含氮有機化合物,分子式C10H11NO2,屬於2-氨基茚滿衍生物,1990年代由普渡大學的David E. Nichols團隊開發[2],結構與MDAT類似[3],能作為選擇性血清素釋放劑(SSRA)[4]。
參考文獻
[編輯]- ^ Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-07-24 (2023-07-25) [2023-08-27]. (原始內容存檔於2023-08-27) (巴西葡萄牙語).
- ^ Johnson MP, Conarty PF, Nichols DE. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. European Journal of Pharmacology. July 1991, 200 (1): 9–16. PMID 1685125. doi:10.1016/0014-2999(91)90659-e.
- ^ Pinterova N, Horsley RR, Palenicek T. Synthetic Aminoindanes: A Summary of Existing Knowledge. Frontiers in Psychiatry (Frontiers Media SA). 17 November 2017, 8: 236. PMC 5698283 . PMID 29204127. doi:10.3389/fpsyt.2017.00236 .
- ^ Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA. Aminoindanes--the next wave of 'legal highs'?. Drug Testing and Analysis (Wiley). 2011, 3 (7-8): 479–482. PMID 21748859. doi:10.1002/dta.318.